Stugeron

Critical Warnings & Restrictions (Safety First)

Basic Stugeron Information

• INN (International Nonproprietary Name): Cinnarizine.
• Brand Names Available In Australia: Not registered in public formulary.
• ATC Code: N07CA02 — nervous system; other nervous system drugs; calcium channel blockers for vestibular disorders.
• Forms & Dosages: Oral tablet 25 mg most common; extended‑release tablets in some markets; syrup/suspension in select regions.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not registered in public formulary.
• OTC / Rx Classification: Mostly OTC in EU/UK for motion sickness; in Australia availability varies with TGA status and it is not PBS‑listed.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Cinnarizine carries specific safety flags that affect who should not take it or who needs close monitoring.

• Absolute Contraindications: Known allergy to cinnarizine or excipients.
• Absolute Contraindications: Disorders of porphyrin metabolism (porphyria).
• Absolute Contraindications: Severe hepatic impairment.
• Absolute Contraindications: Pregnancy and breastfeeding — avoid unless clinician approves.
• Relative Contraindication: Parkinson’s disease — may worsen parkinsonian symptoms.
• Elderly: Higher risk of confusion, extrapyramidal effects and sedation; dose reduction and close monitoring advised.
• Liver/Renal Impairment: Consult prescriber because hepatic metabolism via CYP2D6 is significant.

• Recommended Actions Before Starting: GP or specialist review for high‑risk patients.
• Pharmacist Follow‑Up: Contact patient within 3–7 days of initiation to check sedation and adverse effects.
• Monitoring: Regular review of motor symptoms in Parkinson’s disease and cognitive signs in older adults.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Cinnarizine commonly causes drowsiness and impaired alertness which can affect driving and safety‑critical work.

Patients must not drive, operate heavy machinery or perform safety‑critical tasks until they know how the medicine affects them.

Australian occupational safety laws (Safe Work Australia) require workers to avoid impaired performance and employers should advise on fitness for work where medication could reduce alertness.

Mixing cinnarizine with alcohol or other central nervous system depressants increases the risk of drowsiness and should be avoided.

• Before You Drive / Return To Work Checklist: No alcohol within several hours of dosing.
• Before You Drive / Return To Work Checklist: Do a trial day at home after the first dose to assess sedation.
• Before You Drive / Return To Work Checklist: Avoid operating machinery until you are certain you are not drowsy.
• Before You Drive / Return To Work Checklist: If your role is safety‑critical, check with your GP or pharmacist and document advice.

Q&A — Can I Drive After Taking It In Australia?

Do not drive or operate heavy machinery until you are certain cinnarizine does not make you sleepy or slow your reactions.

If you feel drowsy or less alert after taking cinnarizine, do not drive.

Under Australian workplace and road rules, being impaired by medication can lead to legal and workplace consequences.

Check with your GP or pharmacist if your role is safety‑critical before returning to work or driving after starting cinnarizine.

Usage Basics

INN, Brand Names And Australian Availability

The International Nonproprietary Name is cinnarizine and the familiar brand internationally is Stugeron.

Typical tablet strength is 25 mg and packaging in other countries commonly includes blister packs of 10, 20, 25, 30 or bulk bottles of 100 tablets.

In Australia, cinnarizine is not registered in the public formulary which means it may not be widely stocked or PBS‑subsidised locally.

Some products may be available through private import, specialist clinics or via telehealth prescriptions depending on TGA pathways.

• INN: Cinnarizine.
• Common Brand Names: Stugeron and generics internationally.
• Form Factors: 25 mg tablet most common; syrup or extended‑release in select markets.

Legal Classification (TGA Approval, PBS Status)

Because cinnarizine is not on the Australian public formulary its availability depends on TGA registration and supplier decisions.

It is often sold OTC in Europe and the UK, but in Australia it is not PBS‑listed and may be unregistered or supplied under special pathways.

Patients should confirm whether a product is TGA‑registered or being supplied under the Special Access Scheme or personal importation rules.

Prescriptions, patient information leaflets and pharmacist counselling are recommended whenever supply is off‑label or via importation.

Dosing Guide

Standard Regimens (Practical Australian Reference)

Typical adult dosing depends on the condition being treated.

• Motion Sickness: 25 mg two hours before travel, repeat every eight hours if required.
• Vertigo / Vestibular Disorders: 25 mg three times daily (total 75 mg/day).
• Cerebral / Peripheral Circulatory Disorder: 25 mg two to three times daily as directed.
• Children: Not recommended under 5 years; ages 5–12 years 12.5 mg two to three times daily.
• Elderly: Consider lower doses because of sedation and confusion risk.

Adjustments For Comorbidities

Reduce dose or avoid in severe hepatic impairment, porphyria or Parkinson’s disease.

Monitor closely when used with CYP2D6 inhibitors as hepatic clearance may be altered.

Coordinate care with the patient’s GP and pharmacist for multi‑morbidity patients to review the full medication list.

• When To Consult Prescriber: Liver disease or severe kidney impairment.
• When To Consult Prescriber: Pregnancy or breastfeeding.
• When To Consult Prescriber: Older age with cognitive issues or history of movement disorders.
• When To Consult Prescriber: Multiple CNS depressant medications or alcohol use.

Q&A — What If I Miss A Dose?

Take the missed dose as soon as you remember unless it is almost time for the next dose, in which case skip the missed dose and continue as normal.

Do not double up to catch up on missed doses.

For single pre‑travel dosing do not re‑dose unless nausea recurs and timing fits the guidance.

Seek urgent advice for accidental overdose as symptoms can include drowsiness, confusion and, rarely, seizures.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol markedly increases drowsiness with cinnarizine and should be avoided while taking the medicine.

Caffeine may mask sedation but will not prevent reduced reaction time or other central effects.

In hot, humid Australian summers dehydration can worsen dizziness; remain well hydrated and avoid alcohol before exposure to heat.

• Avoid / Limit: Alcohol while taking cinnarizine.
• Avoid / Limit: Large amounts of caffeine as a way to counter sedation — this is unreliable.
• Summer Safety: Keep hydrated and avoid long sun exposure if feeling dizzy.

Common Drug Conflicts

Cinnarizine has significant interactions to watch for in clinical practice.

Additive central nervous system depression occurs with benzodiazepines, opioids and sedating antihistamines.

Anticholinergic burden increases when combined with tricyclic antidepressants and some antipsychotics.

Pharmacokinetic interactions can occur with CYP2D6 inhibitors such as some SSRIs, potentially altering cinnarizine clearance.

User Reports & Trends (Australian Patient Feedback)

Patients commonly ask whether stugeron will make them sleepy and whether it is worth importing for travel.

• Common Praises: Good efficacy for motion sickness and travel nausea in many reports.
• Common Complaints: Frequent reports of sedation and morning drowsiness after night doses.
• Long‑Term Reports: Some long‑term users note mild weight gain or mood changes.
• Price Sensitivity: Australian buyers often compare imported Stugeron with PBS‑subsidised alternatives and report cost concerns.

Clinicians and pharmacists should document adverse events with the TGA to improve local safety data.

Access & Purchase Options (Australia)

National Chains And Brick‑And‑Mortar Access

Major Australian pharmacy groups such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly stock PBS and OTC motion sickness options but may not stock cinnarizine due to non‑registration.

Ask the pharmacist about generic equivalents or private import options if a specific product like Stugeron is preferred.

• Step 1: Ask your local pharmacist whether cinnarizine is stocked or can be ordered.
• Step 2: Check TGA registration or importation status for the specific product.
• Step 3: Consider effective PBS‑listed alternatives if cost or supply is an issue.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth clinicians can supply prescriptions when cinnarizine is appropriate and importation is possible under TGA pathways such as the Special Access Scheme or personal importation rules.

Only use registered Australian online pharmacies and verify TGA status before purchasing.

In our online pharmacy, stugeron is available without a prescription, with discreet delivery to Australia in 9‑21 days.

Rural patients should plan ahead as small rural pharmacies may need to order stock and lead times can be longer.

Mechanism & Pharmacology

Simplified Explanation For Patients

Cinnarizine is a calcium channel blocker with action on the vestibular system which helps reduce motion‑induced nausea and vertigo.

It also has antihistaminic and antimuscarinic effects that contribute to reduced nausea and a calming of inner‑ear signals.

• ATC Code: N07CA02.
• Vestibular Suppressant: Reduces overactive signals from the inner ear.
• CYP2D6 Metabolism: Metabolised in the liver; drug interactions possible.

Clinical Terms (For Clinicians)

Pharmacokinetics: orally absorbed with typical 25 mg tablet dosing and hepatic metabolism primarily via CYP2D6.

Side‑effect profile includes sedation, anticholinergic symptoms and rare extrapyramidal reactions with prolonged use.

Interactions occur with CNS depressants and strong CYP2D6 inhibitors and it is contraindicated in porphyria and pregnancy.

Indications & Off‑Label Uses

Approved Indications (International Context; Australian Note)

Check TGA‑registered indications for any local product before prescribing or supplying.

Off‑Label Uses In Australian Clinical Practice

Clinicians sometimes consider cinnarizine for chronic vestibular migraine, chronic subjective dizziness or cerebrovascular insufficiency when alternatives fail, but evidence varies.

Off‑label prescribing requires informed consent, clear documentation and a monitoring plan, and PBS‑listed safer options should be considered first.

• Before Off‑Label Use: Review the evidence.
• Before Off‑Label Use: Obtain informed consent and document rationale.
• Before Off‑Label Use: Set up a monitoring and follow‑up plan.

Key Clinical Findings (2022–2026 Summary)

Recent literature supports cinnarizine’s efficacy for motion‑induced nausea and some vestibular conditions but head‑to‑head data with meclizine and promethazine show mixed results and differences in sedation profiles.

Safety literature consistently emphasises the risk of extrapyramidal symptoms with long‑term use and higher adverse event rates in older adults.

Australian data are limited because cinnarizine is not widely registered locally; clinicians should extrapolate cautiously from EU/UK studies and report outcomes to the TGA.

• Efficacy Highlights: Effective for motion sickness and some forms of vertigo in multiple international studies.
• Safety Alerts: Extrapyramidal reactions with prolonged use and pronounced sedation in elderly patients.
• Practice Point: Prefer short‑term use for travel and careful monitoring for chronic indications.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Pros And Cons Checklist

• Consider sedation risk when choosing therapy for drivers or safety‑critical workers.
• Check pregnancy and breastfeeding status before selecting treatment.
• Consider PBS subsidy if out‑of‑pocket cost is a barrier for the patient.
• Review comorbidities such as glaucoma or benign prostatic hyperplasia that may be affected by anticholinergic drugs.

Common Questions (Pharmacy Consultation FAQs)

• Is It Safe In Pregnancy? — Generally avoid; pregnancy is a contraindication unless a clinician explicitly approves.
• How Long Until It Works? — For motion sickness, take 25 mg about two hours before travel for best effect; onset varies by person.
• Can Children Take It? — Not recommended under 5 years; ages 5–12 use lower dosing (12.5 mg two to three times daily).
• What Are The Main Side Effects? — Drowsiness, dry mouth, headache and, rarely with prolonged use, movement disorders.
• When To Refer To GP — Pregnancy, neurological signs, severe liver disease or suspected drug interactions.

Price & Access Comparison (Practical Table)

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

• Rural Checklist: Order lead time — allow extra time for rural deliveries and consider PBS alternatives if timing is critical.

Registration & Regulation

TGA Approval And Regulatory Pathways

Because cinnarizine is not on the Australian public formulary, options for access include checking for TGA‑registered products, applying via the Special Access Scheme or using Authorised Prescriber pathways, or personal importation within TGA rules.

Ensure compliance with TGA labelling and adverse‑event reporting requirements when importing or supplying off‑label.

PBS Subsidy Details

Cinnarizine is not PBS‑listed so there is no standard subsidy for the medicine in Australia.

Patients who need financial support should discuss PBS‑listed alternatives with their GP or pharmacist.

Storage & Handling

Household Storage In Australian Climate

Store cinnarizine tablets in a cool, dry place away from direct sunlight and moisture at room temperature.

In hot or humid Australian regions avoid keeping tablets in car gloveboxes or bathrooms where heat and humidity are high.

Keep the product in original packaging and out of reach of children.

• Keep between typical room temperatures and away from direct heat.
• Protect from humidity and sunlight.
• Use childproof storage and document expiry dates.

Cold‑Chain And Pharmacy Handling

No cold chain is required for routine storage of cinnarizine tablets.

Pharmacies should monitor stock expiry dates and protect stock from prolonged heat exposure during summer deliveries.

Guidelines For Proper Use (Practical Counselling)

Australian Pharmacist Counselling Style (Scripted Points)

• Confirm the indication and explain that the INN is cinnarizine and typical tablet strength is 25 mg.
• Explain dosing: for travel 25 mg two hours before departure and for vertigo 25 mg three times daily.
• Warn about sedation and advise not to drive until they know how they react.
• Screen for contraindications including porphyria, pregnancy, Parkinson’s and severe liver disease.
• Review all current medicines for interactions, especially CNS depressants and strong CYP2D6 inhibitors.
• Explain missed dose guidance and outline overdose symptoms and emergency steps.
• Document counselling in the patient record and provide written consumer information.

Patient handout template: include INN, dose schedule, key warnings (no alcohol, no driving if drowsy), contraindications and contact details for adverse events.

Patient Advice From National Authorities

Advise patients to consult TGA resources and to report adverse events via TGA reporting systems.

When travelling, recommend carrying a written medication list, emergency contacts and a copy of the product information.

End‑user materials should reference peer‑reviewed evidence where possible and clearly state local regulatory status.

Delivery Across Australia

Trust And Next Steps

If a patient is considering cinnarizine for travel sickness, remind them that alternatives such as hyoscine or dimenhydrinate may be more readily available and PBS‑subsidised.

For chronic vestibular conditions, arrange GP review and consider referral to ENT or a vestibular physiotherapist if symptoms persist despite therapy.

Document any adverse effects and report them to the TGA to help build Australian safety data on stugeron use.

When in doubt, pharmacists should consult product data and liaise with the prescriber to ensure safe, cost‑effective care.